10,000 Structures Are Not Enough: The Data Gap Limiting De Novo Antibody Design – Part 2
What if the breakthrough in AI-driven protein therapeutics hinges less on machine learning algorithms and more on a bold rethink of how companies share their most valuable resource—data?
10,000 Structures Are Not Enough: The Data Gap Limiting De Novo Antibody Design – Part 1
There’s a reason so many “picture-perfect” protein designs never make it past the computer screen: the leap from simulation to real-world function is wider than it looks.
Neither Small Molecule nor Biologic: The Cyclodextrin Dimer CMC Challenge – Part 2
Is a future without heart attacks and strokes within reach—not just delayed, but truly reversed?
Neither Small Molecule nor Biologic: The Cyclodextrin Dimer CMC Challenge – Part 1
What if the boldest therapeutic breakthroughs begin with questioning the very boxes we use to define drugs?
Is CFD Overkill for Your Scale-Up? Why It Belongs in Every Biotech Scientist’s Toolkit – Part 2
Bioreactor scale-up failures are still one of the top reasons promising cell therapies never reach the clinic. Traditional “power per volume” scale-up is often just a best guess—putting product quality and timelines at risk.
Is CFD Overkill for Your Scale-Up? Why It Belongs in Every Biotech Scientist’s Toolkit – Part 1
Can computational fluid dynamics (CFD) join the ranks of everyday tools in bioprocess engineering—right alongside spreadsheets and pH meters?
The Fool’s Game That Became Standard Practice: Perfusion, the ATF, and What Changed – Part 2
How do you know when your biotech startup is ready to sell—before the product is “perfect”?
The Fool’s Game That Became Standard Practice: Perfusion, the ATF, and What Changed – Part 1
Most bioprocess innovation is dismissed as a “fool’s game”—until the skeptics are proven wrong.
Batch-to-Batch Variability Is a Design Failure, Not the Norm – Part 2
Biotech startups face a labyrinth of decisions when it comes to manufacturing strategy.
Batch-to-Batch Variability Is a Design Failure, Not the Norm – Part 1
What if batch-to-batch variability was no longer just “part of the job” in tissue engineering and in vitro biology?